Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd Management

Management Kriterienprüfungen 3/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Da Jun Zhao

Geschäftsführender

CN¥1.9m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	89.9%
Amtszeit als Geschäftsführer	22.5yrs
Eigentum des Geschäftsführers	1.5%
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	4.1yrs

Jüngste Management Updates

Recent updates

Earnings Troubles May Signal Larger Issues for Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd (HKG:1349) Shareholders

May 06

What To Know Before Buying Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) For Its Dividend

Apr 12

We Think Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Can Manage Its Debt With Ease

Mar 22

Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?

Mar 07

Are Strong Financial Prospects The Force That Is Driving The Momentum In Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s HKG:1349) Stock?

Feb 20

Could The Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Ownership Structure Tell Us Something Useful?

Feb 07

Should Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Be Disappointed With Their 38% Profit?

Jan 25

Should You Rely On Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's (HKG:1349) Earnings Growth?

Jan 12

Would Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Be Valuable To Income Investors?

Dec 28

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Seems To Use Debt Rather Sparingly

Dec 15

Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?

Dec 03

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s (HKG:1349) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Nov 21

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Da Jun Zhao im Vergleich zu den Einnahmen von Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	CN¥102m
Dec 31 2023	CN¥2m	CN¥2m	CN¥109m
Sep 30 2023	n/a	n/a	CN¥191m
Jun 30 2023	n/a	n/a	CN¥242m
Mar 31 2023	n/a	n/a	CN¥142m
Dec 31 2022	CN¥3m	CN¥2m	CN¥138m
Sep 30 2022	n/a	n/a	CN¥132m
Jun 30 2022	n/a	n/a	CN¥112m
Mar 31 2022	n/a	n/a	CN¥213m
Dec 31 2021	CN¥5m	CN¥2m	CN¥213m
Sep 30 2021	n/a	n/a	CN¥198m
Jun 30 2021	n/a	n/a	CN¥201m
Mar 31 2021	n/a	n/a	CN¥188m
Dec 31 2020	CN¥3m	CN¥1m	CN¥165m
Sep 30 2020	n/a	n/a	CN¥191m
Jun 30 2020	n/a	n/a	CN¥165m
Mar 31 2020	n/a	n/a	CN¥204m
Dec 31 2019	CN¥3m	CN¥1m	CN¥227m
Sep 30 2019	n/a	n/a	CN¥151m
Jun 30 2019	n/a	n/a	CN¥151m
Mar 31 2019	n/a	n/a	CN¥91m
Dec 31 2018	CN¥2m	CN¥1m	CN¥112m
Sep 30 2018	n/a	n/a	CN¥95m
Jun 30 2018	n/a	n/a	CN¥78m
Mar 31 2018	n/a	n/a	CN¥77m
Dec 31 2017	CN¥1m	CN¥1m	CN¥75m

Vergütung im Vergleich zum Markt: Da JunDie Gesamtvergütung ($USD307.06K) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Hong Kong ($USD490.97K).

Entschädigung vs. Einkommen: Da JunDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Da Jun Zhao (54 yo)

22.5yrs

Amtszeit

CN¥1,882,870

Vergütung

Mr. Da Jun Zhao has been an Executive Director at Taizhou SPH Pharmaceutical Co., Ltd. since January 2002. Mr. Zhao Co-Founded Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.in November 1996 and ser...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Da Jun Zhao	Co-Founder	22.5yrs	CN¥1.88m	1.51% CN¥ 81.1m
Xue Yan	CFO, Deputy GM	1.2yrs	CN¥1.18m	0.20% CN¥ 10.5m
Xiao Yang Yu	Non-Executive Director	11.2yrs	keine Daten	keine Daten
Ai Guo Zhou	Member of Supervisory Committee	no data	keine Daten	keine Daten
Bo Shen	Non Executive Director	12.1yrs	keine Daten	keine Daten
Jian Huang	Independent Chairman of Supervisory Committee	7.1yrs	keine Daten	keine Daten
Hong Guang Wang	Independent Non-Executive Director	1.2yrs	CN¥116.67k	keine Daten
Siu Wing Lam	Independent Non-Executive Director	1.2yrs	keine Daten	keine Daten
Pei Long Xu	Independent Non-Executive Director	1.2yrs	CN¥116.67k	keine Daten
Ya Nan Qu	Member of Supervisory Committee	no data	keine Daten	0.0038% CN¥ 202.2k

4.1yrs

Durchschnittliche Betriebszugehörigkeit

54yo

Durchschnittliches Alter

Erfahrener Vorstand: 1349Die Vorstandsmitglieder gelten als erfahren (4 Jahre durchschnittliche Amtszeit).

Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Upcoming dividend of CN¥0.07 per share

Earnings Troubles May Signal Larger Issues for Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd (HKG:1349) Shareholders

First quarter 2024 earnings released

Now 21% overvalued

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. to Report Q2, 2024 Results on Aug 15, 2024

Full year 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.13 in FY 2022)

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Application

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Investigational New Drug

Third quarter 2023 earnings released: EPS: CN¥0.021 (vs CN¥0.11 in 3Q 2022)

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Acceptance Notice Issued by the National Medical Products Administration of the PRC

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Announces First Patient Enrolled in Phase I Clinical Trial of FZ-AD004 Antibody Drug Conjugate for the Treatment of Advanced Solid Tumors

Less than half of directors are independent

Upcoming dividend of CN¥0.07 per share at 2.7% yield

First quarter 2023 earnings released: EPS: CN¥0.01 (vs CN¥0.005 in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.20 in FY 2021)

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Acceptance Notice for the Investigational New Drug Application

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Announces Indicative Announcement-First Patient Enrolled in Phase I Clinical Trial of FDA022 Antibody Drug Conjugate for Injection for the Treatment of Advanced Solid Tumors

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Acceptance Notice Issue by the National Medical Products Administration of the PRC

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.046 in 3Q 2021)

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. to Report Q3, 2022 Results on Oct 27, 2022

Second quarter 2022 earnings released

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Announces Supplemental Announcement Related to Earnings Guidance for the Six Months Ended 30 June 2022

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Received the Acceptance Notice of the Quality and Efficacy Consistency Evaluation of Generic Drugs for Chemical Injection

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Approves Final Dividend for the Year Ended 31 December 2021, Payable on or Before 26 August 2022

Upcoming dividend of CN¥0.07 per share

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives the Acceptance Notice Issued by the National Medical Products Administration of the Prc

First quarter 2022 earnings released

Less than half of directors are independent

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. to Report Q1, 2022 Results on Apr 29, 2022

Full year 2021 earnings released: EPS: CN¥0.21 (vs CN¥0.17 in FY 2020)

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Proposes Final Dividend for the Year Ended 31 December 2021, Payable on 26 August 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released

Second quarter 2021 earnings released: EPS CN¥0.058 (vs CN¥0.045 in 2Q 2020)

Upcoming dividend of CN¥0.05 per share

First quarter 2021 earnings released

What To Know Before Buying Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) For Its Dividend

Full year 2020 earnings released

We Think Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Can Manage Its Debt With Ease

Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

Are Strong Financial Prospects The Force That Is Driving The Momentum In Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s HKG:1349) Stock?

Could The Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Ownership Structure Tell Us Something Useful?

Should Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Be Disappointed With Their 38% Profit?

New 90-day high: HK$4.67

Investor sentiment improved over the past week

Should You Rely On Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's (HKG:1349) Earnings Growth?

Would Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Be Valuable To Income Investors?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Seems To Use Debt Rather Sparingly

Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s (HKG:1349) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Third quarter earnings released

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 29, 2020

New 90-day low: HK$3.65

New 90-day low - HK$4.10

New 90-day low - HK$4.95

Earnings released

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter